A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma

Checkpoint blockade has revolutionized the treatment of melanoma; however, it benefits only the minority of patients. Several agents have been combined with immunotherapy to improve T-cell activation and persistence including growth factor, chemotherapy, and radiation. Preclinical data suggest that...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Immunother
Main Authors: Patel, Sapna P., Kim, Dae Won, Bassett, Roland L., Cain, Suzanne, Washington, Edwina, Hwu, Wen-Jen, Kim, Kevin B., Papadopoulos, Nicholas E., Homsi, Jade, Hwu, Patrick, Bedikian, Agop Y.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5898971/
https://ncbi.nlm.nih.gov/pubmed/28612140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-017-2030-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados